Mutations in KLK6 Gene Region Can Predict Risk of Aggressive Disease in Prostate Cancer Patients

Mutations in KLK6 Gene Region Can Predict Risk of Aggressive Disease in Prostate Cancer Patients
Genetic mapping of the Kallikrein 6, or KLK6, gene region — which could be a hotspot for the occurrence of prostate cancer-associated mutations — may help doctors identify which patients are at risk of developing an aggressive form of the disease, according to Canadian researchers. Their study, “Germline Mutations in the Kallikrein 6 Region and Predisposition for Aggressive Prostate Cancer,” recently appeared in the Journal of the National Cancer Institute. "As an oncologist I know firsthand how valuable it would be to have a genetic tool that could help choose the best course of action with my patients," the study's senior author, Alexandre Zlotta, MD, said in a press release. "It would help spare patients with indolent disease from unnecessary treatments and their side effects, and aid in the diagnosis and directing patients with aggressive disease to the appropriate treatment." Zlotta is director of uro-oncology at Toronto's Mount Sinai Hospital, and researcher with the Lunenfeld-Tanenbaum Research Institute. Also on the team was Paul Boutros, MD, principal investigator at the Ontario Institute for Cancer Research (OICR). The study evaluated the occurrence of genetic alterations in the Kallikrein (KLK) genetic region in a cohort of 1,858 men with aggressive prostate cancer. This region is kno
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *